CN107311990A - 一种奥美沙坦酯的制备方法 - Google Patents
一种奥美沙坦酯的制备方法 Download PDFInfo
- Publication number
- CN107311990A CN107311990A CN201710611671.5A CN201710611671A CN107311990A CN 107311990 A CN107311990 A CN 107311990A CN 201710611671 A CN201710611671 A CN 201710611671A CN 107311990 A CN107311990 A CN 107311990A
- Authority
- CN
- China
- Prior art keywords
- preparation
- alkali
- methyl
- olmesartan medoxomil
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 title claims abstract description 25
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 229960001199 olmesartan medoxomil Drugs 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 18
- ABPZRLQZVHPPCT-UHFFFAOYSA-N 5-trityl-2h-tetrazole Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=NNN=N1 ABPZRLQZVHPPCT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 230000007062 hydrolysis Effects 0.000 claims abstract description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 11
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- -1 Methylethyl Chemical group 0.000 claims abstract description 4
- 238000010612 desalination reaction Methods 0.000 claims abstract description 4
- 125000006239 protecting group Chemical group 0.000 claims abstract description 3
- 238000006467 substitution reaction Methods 0.000 claims abstract description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 17
- 239000003513 alkali Substances 0.000 claims description 16
- 239000002585 base Substances 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000003495 polar organic solvent Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- YLXJPSMRVVGWKM-UHFFFAOYSA-N C(C1=CC=CC=C1)[Br+2] Chemical compound C(C1=CC=CC=C1)[Br+2] YLXJPSMRVVGWKM-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- FXIRZTCXQPBQFK-UHFFFAOYSA-N [O]S(=O)(=O)c1ccc(cc1)[N+]([O-])=O Chemical compound [O]S(=O)(=O)c1ccc(cc1)[N+]([O-])=O FXIRZTCXQPBQFK-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- UKFWSNCTAHXBQN-UHFFFAOYSA-N ammonium iodide Chemical compound [NH4+].[I-] UKFWSNCTAHXBQN-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 claims 1
- QYIOFABFKUOIBV-UHFFFAOYSA-N 4,5-dimethyl-1,3-dioxol-2-one Chemical class CC=1OC(=O)OC=1C QYIOFABFKUOIBV-UHFFFAOYSA-N 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- LZZHUQKJWKRUOS-UHFFFAOYSA-N propan-2-yl 1h-imidazole-5-carboxylate Chemical class CC(C)OC(=O)C1=CNC=N1 LZZHUQKJWKRUOS-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000032050 esterification Effects 0.000 abstract description 7
- 238000005886 esterification reaction Methods 0.000 abstract description 7
- 239000002699 waste material Substances 0.000 abstract description 6
- 238000005406 washing Methods 0.000 abstract description 5
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 239000003960 organic solvent Substances 0.000 abstract description 4
- 238000005804 alkylation reaction Methods 0.000 abstract description 3
- 238000010511 deprotection reaction Methods 0.000 abstract description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 abstract description 2
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical class C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 abstract 1
- KYZHGCSTFZUHIH-UHFFFAOYSA-N 2-propylimidazole Chemical compound CCCC1=NC=C[N]1 KYZHGCSTFZUHIH-UHFFFAOYSA-N 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- HWYHDWGGACRVEH-UHFFFAOYSA-N n-methyl-n-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000011084 recovery Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- LZTRCELOJRDYMQ-UHFFFAOYSA-N triphenylmethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1=CC=CC=C1 LZTRCELOJRDYMQ-UHFFFAOYSA-N 0.000 description 8
- 235000011167 hydrochloric acid Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- WHPJQURVXHUXQD-UHFFFAOYSA-N benzene;bromomethane Chemical compound BrC.C1=CC=CC=C1 WHPJQURVXHUXQD-UHFFFAOYSA-N 0.000 description 5
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IJOPLMOXIPGJIJ-UHFFFAOYSA-N (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate Chemical compound C=1C=C(C=2C(=CC=CC=2)C=2N(N=NN=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C IJOPLMOXIPGJIJ-UHFFFAOYSA-N 0.000 description 4
- 0 CCCc1nc(C(C)(C)*)c(C(OCC)=O)[n]1 Chemical compound CCCc1nc(C(C)(C)*)c(C(OCC)=O)[n]1 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000004683 dihydrates Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical group [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明提供了一种改进的奥美沙坦酯合成方法,包括:由乙基‑4‑(1‑羟基‑1‑甲基乙基)‑2‑丙基咪唑‑5‑羧酸酯与4‑[2‑(三苯甲基四唑‑5‑基)苯基]苯甲基溴发生烷化反应,酯基水解后,与4‑取代的甲基‑5‑甲基‑2‑氧代‑1,3‑二氧杂环戊烯衍生物,发生亲核取代反应成酯;再脱去三苯甲基保护,得到奥美沙坦酯。本发明“一锅法”完成烷化、水解、酯化和脱保护基反应,中间没有分离纯化过程。所需仪器设备少,工艺简单;整个过程只用一种有机溶剂,有利于工业化生产;使用过滤除盐代替萃取洗涤操作,“三废”少,绿色环保。
Description
技术领域
本发明涉及一种降血压药物奥美沙坦酯的制备方法,属医药化工领域。
背景技术
奥美沙坦酯是由日本第一三共公司研制开发的一种口服有效的非肽类血管紧张素Ⅱ受体拮抗剂。奥美沙坦酯化学名为2,3-二羟基-2-丁烯基-4-(1-羟基-1-甲基乙基)-2-丁基-1-[4-(2-1H-四唑-5-苯基)苄基]咪唑-5-羧酸酯环-2,3-碳酸酯,结构式如式1所示:
专利CN101238119A披露了一种奥美沙坦酯改进的制备方法。以乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(2)和4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(3)为起始原料,经烷化反应得到中间体4,其中反应溶剂和结晶溶剂均为乙腈,之后再经过一锅法完成水解、酯化和去保护,得到奥美沙坦酯(1),如路线1所示:
其中水解、酯化步骤在DMA(N,N-二甲基乙酰胺)中完成;完成水解、酯化步骤后,通过将乙酸乙酯和盐水一起加入反应混合物中,三苯甲基奥美沙坦酯再被萃取出来。该合成方法操作较为简单,产品收率和纯度较高,但存在溶剂种类多,难回收,生产成本高、“三废”量大等问题。
PCT专利WO 2007148344A2公开一种奥美沙坦酯的制备方法,该方法也是以乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(2)和4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(3)为起始原料,在催化剂作用下经烷化反应得到中间体4,再经氢氧化钾在异丙醇中水解得到三苯甲基奥美沙坦酸二水合物(8),然后再经一锅法酯化和去保护,得到奥美沙坦酯(1),如路线2所示:
其中合成三苯甲基奥美沙坦酸二水合物(8)操作,也是通过乙酸乙酯和盐水一起加入浓缩物中,经乙酸乙酯萃取,再蒸馏掉乙酸乙酯得到的,且烷化、水解、酯化和脱保护所用的溶剂都不同,同样存在溶剂种类多,难回收,生产成本高、“三废”量大等问题。
美国专利US 8076492B公开了一种奥美沙坦酯的制备方法,该方法也是以乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(2)和4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(3)为起始原料,经一锅法烷化,酯化和脱保护得到奥美沙坦酯(1),如路线3所示:
该方法操作方便,但水解、酯化反应所用的碱是大量的二异丙基乙基胺,会产生高盐高氨氮高COD的废水,工业上很难处理。另外,纯化奥美沙坦酯时二氯甲烷萃取,需要用大量水洗涤,浓缩后,再用丙酮重结晶,且收率仅为47.3%。
中国专利CN101778843B公开一种奥美沙坦的制备方法,该方法包括以乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(2)和4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(3)为起始原料,经烷化、水解、酯化反应一锅法制备三苯甲基奥美沙坦酯,再加入另一种反应溶剂在酸条件下脱保护得到奥美沙坦酯。如路线4所示:
其中在烷化、水解、酯化反应所用的碱均为氢氧化锂,溶剂为DMA,成本较高。后处理需要加入大量水使中间体6析出,还需要在过滤时加大量水洗涤除去DMA,“三废”量较大。
因此开发一种操作简便,绿色环保,适合工业化大生产的奥美沙坦酯制备方法具有十分重要的意义。
发明内容
本发明克服了现有技术存在的放大生产成本高、溶剂回收压力大、操作繁琐等缺点,提供了一种更为简短高效、经济实用、绿色环保,并且总收率高达80%以上,生产周期短,具有明显的成本优势,适合工业化生产。
为解决上述的问题,本发明采用如下技术方案:
a)将乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)在极性有机溶剂、第一种碱和催化剂的存在下,与4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III)发生烷化反应;
b)加入第二种碱,发生水解反应;
c)再加入4-取代的甲基-5-甲基-2-氧代-1,3-二氧杂环戊烯衍生物(V),发生亲核取代反应成酯;
d)反应液过滤除盐,加入水和酸,脱去三苯甲基保护,过滤;
e)反应液滴加碱,调节pH,降温析晶,得到奥美沙坦酯;
合成路线如下所示:
其中R为离去基团,选自卤素、对甲苯磺酰氧、对硝基苯磺酰氧、对溴苯磺酰氧、甲基磺酰氧,优选为卤素,进一步优选为氯,溴,碘;
其中所述步骤a),步骤b),步骤c),步骤d)的产物不分离纯化;
且所述步骤a),步骤b),步骤c),步骤d)和步骤e)中的反应溶剂均相同。
优选地,本发明所述的催化剂为无机碘盐,选自LiI、NaI、KI或NH4I,优选KI。
优选地,本发明所述的极性有机溶剂选自THF、丙酮,乙腈、二氧六环,优选为丙酮。
优选地,本发明所述的第一种碱选自Na2CO3、K2CO3、Cs2CO3、甲醇钠、叔丁醇钾、Na3PO4、Na2HPO4、K3PO4或K2HPO4,优选为K2CO3。
优选地,本发明所述的第二种碱选自NaOH、KOH、CsOH或Ba(OH)2,优选为KOH。
优选地,本发明所述的酸选自盐酸、溴化氢、碘化氢、硫酸或磷酸,优选为盐酸。
优选地,本发明所述步骤e)调节pH至3~5,优选为3.5~4.5。
优选地,本发明所述乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)、4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III)、第一种碱、催化剂、甲基-5-甲基-2-氧代-1,3-二氧杂环戊烯衍生物(V,DMDO-Cl)、水和酸的质量比范围为1:2.5~3:0.8~1.5:0.1~0.3:1.0~1.2:2~5:0.7~1。
优选地,本发明所述乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)与极性有机溶剂的质量体积比范围为1:1~20,优选为1:12.5。
本发明与现有技术相比具有以下的优点:
1.通过“一锅法”完成所有制备过程,生产周期短,产能大,且无萃取洗涤单元操作,所需仪器设备少,工艺简单。
2.整个过程只用到一种有机溶剂,且只需一次性加入,操作简便。另外由于只用到一种有机溶剂,方便了工业生产时溶剂的储存、转移和回收套用。
3.本发明使用过滤除盐代替萃取洗涤操作,“三废”少,绿色环保。
4.本发明具有良好的收率和高纯度的产品,本发明采用的技术方案总收率能达到80%以上,且纯度高,能有效控制杂质,保证产品能够满足药品质量标准。
具体实施方式
下面对本发明优选实施方案进行描述,但是应当理解,这些描述只是为进一步说明本发明的特征和优点,而不是对本发明权利要求的限制。
实施例1
向烧瓶中加入2000g丙酮、160g乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)、150g K2CO3、460g 4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III)、20g KI,升温至回流,保温搅拌反应34~38小时。
再加入102g KOH,回流反应6~8h。降温至10~20℃,加入170g DMDO-Cl,保温搅拌30~60min。升温至回流,反应22~26小时。反应结束后加入40g硅藻土,搅拌30~60分钟,抽滤,200g丙酮淋洗滤饼。
向滤液中加入800g饮用水和200g精制盐酸,室温反应2~4小时,过滤除去副产物三苯基甲醇。滴加10%K2CO3水溶液,调节料液pH至4,降温至10~20℃,搅拌析晶2h,抽滤,滤饼用预冷的45g丙酮和230g饮用水的混合液洗涤,烘干,得到奥美沙坦酯309g,总收率83.1%(相对于乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)),纯度:主峰99.27%,奥美沙坦酸0.08%,三苯基甲醇0.14%,最大未知单杂0.13%。
实施例2
向烧瓶中加入2000g THF、160g乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)、150g K2CO3、460g 4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III)、20g KI,升温至回流,保温搅拌反应34~38小时。
再加入102g KOH,回流反应6~8h。降温至10~20℃,加入170g DMDO-Cl,保温搅拌30~60min。升温至回流,反应22~26小时。反应结束后加入40g硅藻土,搅拌30~60分钟,抽滤,200g THF淋洗滤饼。
向滤液中加入800g饮用水和200g精制盐酸,室温反应2~4小时,过滤除去副产物三苯基甲醇。滴加10%K2CO3水溶液,调节料液pH至4,降温至10~20℃,搅拌析晶2h,抽滤,滤饼用预冷的45g THF和230g饮用水的混合液洗涤,烘干,得到奥美沙坦酯280g,总收率75.3%(相对于乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)),纯度:主峰96.24%,奥美沙坦酸0.10%,三苯基甲醇0.54%,最大未知单杂0.93%。
实施例3
向烧瓶中加入2000g乙腈、160g乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)、150g K2CO3、460g 4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III)、20g KI,升温至回流,保温搅拌反应34~38小时。
再加入102g KOH,回流反应6~8h。降温至10~20℃,加入170g DMDO-Cl,保温搅拌30~60min。升温至回流,反应22~26小时。反应结束后加入40g硅藻土,搅拌30~60分钟,抽滤,200g乙腈淋洗滤饼。
向滤液中加入800g饮用水和200g精制盐酸,室温反应2~4小时,过滤除去副产物三苯基甲醇。滴加10%K2CO3水溶液,调节料液pH至4,降温至10~20℃,搅拌析晶2h,抽滤,滤饼用预冷的45g乙腈和230g饮用水的混合液洗涤,烘干,得到奥美沙坦酯224g,总收率60.3%(相对于乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)),纯度:主峰99.42%,奥美沙坦酸0.03%,三苯基甲醇0.10%,最大未知单杂0.13%。
对比实施例:
根据印度公司Cipla申请专利美国专利US 8076492B公开的奥美沙坦酯制备方法,本发明人重复该试验,具体如下:
将50g乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)、26g K2CO3加入到300mL DMA中,升温至45~50℃,加入135g 4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III),保温反应5小时。于40~45℃加入100mL二异丙基乙基胺,再滴加80g DMDO-Cl溶于160mL DMA的溶液,滴加时间不少于一小时。反应液升温至60~65℃,保温反应4小时,再冷至30~35℃,加入浓盐酸调节至中性。过滤除去无机物,加入10g活性炭脱色,保温40~45℃搅拌30分钟。反应液通过硅藻土过滤。于25~30℃向滤液慢慢加入100mL浓盐酸,升温至60℃搅拌1小时,再降温至0~5℃,过滤除去三苯基甲醇。反应液减压浓缩,加入500ml水,加碱(K2CO3)调节至中性,再加入500mL二氯甲烷萃取。有机层减压浓缩至干,加入少量丙酮拖带,再加入250mL丙酮析晶,得到奥美沙坦酯54g(原专利报道产量55g),总收率46.5%(相对于乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)),纯度:主峰99.10%,奥美沙坦酸0.23%,三苯基甲醇0.17%,最大未知单杂0.21%。
对比试验说明:
1.根据US8076492B的技术方案所得产物收率仅为46.5%,不及本发明的技术方案;
2.后处理繁琐,该对比实施例需要先用二氯甲烷萃取,再用丙酮重结晶,而本发明的技术方案整个过程只需要在反应前一次性加入一种有机溶剂,反应后只需要调PH,降温析晶即可,操作简便,有利于工业化生产。
3.该对比实施例使用二异丙基乙基胺作为碱,而二异丙基乙基胺会产生高盐高氨氮高COD的废水,工业上很难处理,而本发明的技术方案使用的均为常规试剂,“三废少”,绿色环保。
本发明提出的一种奥美沙坦酯的制备方法已通过实施例进行了描述,相关技术人员明显能在不脱离本发明内容、精神和范围内对本文所述的奥美沙坦酯制备方法进行改动或适当变更与组合,来实现本发明技术。特别需要指出的是,所有相类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明的精神、范围和内容中。
Claims (9)
1.一种奥美沙坦酯的制备方法,其特征在于包括以下步骤:
a)将乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)在极性有机溶剂、第一种碱和催化剂的存在下,与4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III)发生烷化反应;
b)加入第二种碱,发生水解反应;
c)再加入4-取代的甲基-5-甲基-2-氧代-1,3-二氧杂环戊烯衍生物(V),发生亲核取代反应成酯;
d)反应液过滤除盐,加入水和酸,脱去三苯甲基保护,过滤;
e)反应液滴加碱,调节pH,降温析晶,得到奥美沙坦酯。
合成路线如下所示:
其中R为离去基团,选自卤素、对甲苯磺酰氧、对硝基苯磺酰氧、对溴苯磺酰氧、甲基磺酰氧,优选为卤素,进一步优选为氯,溴,碘;
其特征在于所述步骤a),步骤b),步骤c),步骤d)的产物不分离纯化;
且所述步骤a),步骤b),步骤c),步骤d)和步骤e)中的反应溶剂均相同。
2.根据权利要求1所述的制备方法,其特征在于,所述的催化剂为无机碘盐,选自LiI、NaI、KI或NH4I,优选KI。
3.根据权利要求1所述的制备方法,其特征在于,所述的极性有机溶剂选自THF、丙酮,乙腈、二氧六环,优选为丙酮。
4.根据权利要求1所述的制备方法,其特征在于,所述的第一种碱选自Na2CO3、K2CO3、Cs2CO3、甲醇钠、叔丁醇钾、Na3PO4、Na2HPO4、K3PO4或K2HPO4,优选为K2CO3。
5.根据权利要求1所述的制备方法,其特征在于,所述的第二种碱选自NaOH、KOH、CsOH或Ba(OH)2,优选为KOH。
6.根据权利要求1所述的制备方法,其特征在于,所述的酸选自盐酸、溴化氢、碘化氢、硫酸或磷酸,优选为盐酸。
7.根据权利要求1所述的制备方法,其特征在于,所述步骤e)调节pH至3~5,优选为3.5~4.5。
8.根据权利要求1所述的制备方法,其特征在于,所述乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)、4-[2-(三苯甲基四唑-5-基)苯基]苯甲基溴(III)、第一种碱、催化剂、甲基-5-甲基-2-氧代-1,3-二氧杂环戊烯衍生物(V)、水和酸的质量比范围为1:2.5~3:0.8~1.5:0.1~0.3:1.0~1.2:2~5:0.7~1。
9.根据权利要求1所述的制备方法,其特征在于,所述乙基-4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯(II)与极性有机溶剂的质量体积比范围为1:1~20,优选为1:12.5。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710611671.5A CN107311990B (zh) | 2017-07-25 | 2017-07-25 | 一种奥美沙坦酯的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710611671.5A CN107311990B (zh) | 2017-07-25 | 2017-07-25 | 一种奥美沙坦酯的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107311990A true CN107311990A (zh) | 2017-11-03 |
CN107311990B CN107311990B (zh) | 2021-09-03 |
Family
ID=60179445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710611671.5A Active CN107311990B (zh) | 2017-07-25 | 2017-07-25 | 一种奥美沙坦酯的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107311990B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109081812A (zh) * | 2018-08-30 | 2018-12-25 | 黄冈鲁班药业股份有限公司 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090108739A (ko) * | 2005-01-03 | 2009-10-16 | 테바 파마슈티컬 인더스트리즈 리미티드 | 불순물의 양이 감소된 올메사탄 메독소밀 |
SI22092A (sl) * | 2005-07-29 | 2007-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo olmesartan medoksomila |
CA2616466A1 (en) * | 2005-07-29 | 2007-02-15 | Krka | Process for the preparation of olmesartan medoxomil |
CZ299902B6 (cs) * | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
US8048904B2 (en) * | 2006-06-19 | 2011-11-01 | Matrix Laboratories Ltd. | Process for the preparation of olmesartan medoxomil |
US8592474B2 (en) * | 2007-08-08 | 2013-11-26 | Lek Pharmaceuticals D.D. | Process for the preparation or purification of olmesartan medoxomil |
WO2011036674A1 (en) * | 2009-09-24 | 2011-03-31 | Inogent Laboratories Private Limited | A new process for the preparation of olmesartan medoxomil |
AR083523A1 (es) * | 2010-10-29 | 2013-03-06 | Interquim Sa | Procedimiento de obtencion del olmesartan medoxomilo |
CN103012382B (zh) * | 2012-12-05 | 2016-10-05 | 迪沙药业集团有限公司 | 一种奥美沙坦酯的制备方法 |
-
2017
- 2017-07-25 CN CN201710611671.5A patent/CN107311990B/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109081812A (zh) * | 2018-08-30 | 2018-12-25 | 黄冈鲁班药业股份有限公司 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物 |
Also Published As
Publication number | Publication date |
---|---|
CN107311990B (zh) | 2021-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111423452B (zh) | 瑞卢戈利的中间体及其制备方法和应用 | |
JP5214608B2 (ja) | 3−(2,2,2−トリメチルヒドラジニウム)プロピオネート・二水和物の製造方法 | |
KR20200018664A (ko) | 오메캄티브 메카빌의 합성 | |
CN109293592A (zh) | 一种制备钆布醇的方法 | |
CN103664912B (zh) | 一种普卡必利的合成工艺 | |
CN102617434B (zh) | 一锅法制备维达列汀 | |
CN105541844A (zh) | 一种高纯度利拉利汀的简易制备方法 | |
CN106699595B (zh) | 一种拉科酰胺制备方法 | |
CN108467355A (zh) | (r)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法 | |
CN108341804A (zh) | 高纯度奥美沙坦酯的制备方法 | |
CN108440409B (zh) | 一种瑞巴匹特的绿色高效制备方法 | |
CN104592081B (zh) | 一种氨曲南主环的合成方法 | |
CN107311990A (zh) | 一种奥美沙坦酯的制备方法 | |
CN106883175A (zh) | 一种托伐普坦的制备方法 | |
JP2011195466A (ja) | 精製3,3’,4,4’−ジフェニルエーテルテトラカルボン酸の製造方法 | |
CN105418477B (zh) | 降低雷迪帕韦中间体中非对映异构体杂质含量的方法 | |
WO2002004430A1 (fr) | Procedes relatifs a l'elaboration de composes de triazine et de sels d'ammonium quaternaire | |
RO121737B1 (ro) | Procedeu de preparare a 5-carboxiftalidei şi utilizarea sa pentru producerea de citalopram | |
CN112479863B (zh) | 一种催化氯化2-甲基苯氧乙酸制备2-甲-4-氯苯氧乙酸的方法 | |
CN114315679A (zh) | 一种乌帕替尼手性中间体的制备方法 | |
CN103304543A (zh) | 一种坎地沙坦酯的制备方法 | |
CN114560862A (zh) | 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法 | |
CN107001250A (zh) | 一种制备奥当卡替中间体的方法 | |
CN101747343B (zh) | 一种舒巴坦匹酯的制备方法 | |
JP3907787B2 (ja) | 安息香酸誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |